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A young female child aged 7 years presented initially
with chronic alopecia areata, which over 2 years
progressed to alopecia areata universalis.
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HISTORY
A young female child aged 7 years presented initially with
chronic alopecia areata, which over 2 years progressed to
alopecia areata universalis. Of clinical importance was her
strong family history of alopecia areata, Hashimoto’s thyroi-
ditis, and type 2 diabetes. Over the next 3 years, she
developed central obesity and a failure to grow in stature.
Investigation revealed that she had celiac disease for which
she was treated with a gluten-free diet. On a 2-year gluten-free
diet, she had a relative minimal change in height and slow
progressive weight gain of 20 lbs. Other findings included
fatigue, polyuria, and polydipsia. During this time, she was a
successful competitive swimmer.
EXAMINATION
On examination, her stature was 55% normal range for her
age, 95% range for her weight, and she had alopecia areata
universalis (Figure 1).
INVESTIGATION
Laboratory evaluation revealed normal but reduced insulin
growth factor 1, which was 73 ng ml1 (normal range
52–345 ng ml 1), and normal thyroid function, adrenal axis,
pituitary, and parathyroid functions. Magnetic resonance ima-
ging revealed normal pituitary, adenohypophysis, neural hypo-
physis, and infundibulum. Her bone age at chronological age of
8 years 9 months was estimated to be 7 years 10 months.
Growth hormone testing confirmed the diagnosis of growth
hormone deficiency, insulin growth factor 1, for which she was
treated with insulin growth factor 1, somatropin. With this
treatment, she experienced an increase in her growth/stature by
16.5 cm per year with an IGF level of 546 ng ml1 (Figure 2).
DISCUSSION
Alopecia areata and celiac disease are autoimmune diseases,
T cell mediated, and shares a common linkage to HLA DQ3
(Naveh et al., 1999; Romanos et al., 2009). In addition, celiac
disease is associated with an autoimmune growth hormone
deficiency (Fessatou et al., 2003). The literature reveals that
treatment of celiac disease does not reverse the growth
retardation, which was the case in this patient (Giovanele
et al., 2006; Scanlon and Murray, 2011). With the
introduction of insulin growth factor 1, somatropin, she
experienced a growth spurt; however, her alopecia areata
universalis was unresponsive and remained unchanged.
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Figure 1. Young female child with progressive alopecia areata universalis.
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Somatotropin therapy
growth hormone (1GF)
Height/Weight/BSA 4/2/12 6/15/12 7/16/12 9/28/12 9/28/12
Height 4’7.906” 4’8.614” 4’9.283” 4’9.953” 4’10.03”
BSA 1.31 1.34 1.35 1.37 1.37
Weight 96.6 lb 99.68 lb 99.96 lb 101.32 lb 101.31 lb
Age 9.64 years was 16.5 cm on 1GF
Figure 2. Growth hormone 1 therapy (somatropin) resulted in an increase in height and a relative decrease in weight.
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